Fennec Pharmaceuticals, Inc. (FENC)
11.74
+0.34
(+2.98%)
USD |
NASDAQ |
Aug 25, 16:00
11.74
0.00 (0.00%)
After-Hours: 17:54
Fennec Pharmaceuticals Gross Profit Margin (Quarterly) : 95.97% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.97% |
| March 31, 2026 | 96.23% |
| December 31, 2025 | 87.20% |
| September 30, 2025 | 94.70% |
| June 30, 2025 | 89.98% |
| March 31, 2025 | 95.74% |
| December 31, 2024 | 91.56% |
| September 30, 2024 | 80.54% |
| June 30, 2024 | 91.63% |
| March 31, 2024 | 97.83% |
| December 31, 2023 | 92.96% |
| September 30, 2023 | 94.92% |
| Date | Value |
|---|---|
| June 30, 2023 | 95.55% |
| March 31, 2023 | 94.34% |
| December 31, 2022 | 94.40% |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Abeona Therapeutics, Inc. | 57.45% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -17.41% |
| Return on Assets | -5.78% |
| Return on Invested Capital | -12.90% |
| Profit Margin (Quarterly) | 11.04% |
| Operating Margin (Quarterly) | 9.72% |
| Return on Net Operating Assets | -11.83% |